Answers are grounded in this paper and cite their sources.
Randomized trial evaluates immunogenicity of a melanoma vaccine with or without varlilumab, suggesting optimizations for combining therapies.
No synergistic toxicity was observed with combination treatment. Similar durability in immunogenicity was found with or without varlilumab. Depletion of circulating CD4+ T cells with varlilumab may have abrogated benefits of inducing tumor-cognate CD4+ T cells with vaccination. Induction of memory responses supports further work to optimize shared antigen vaccines in combination with other immunotherapies.
No takes yet. Share an insight, caveat, or question.
Ninmer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: